Fortress Biotech is a holding-company-style biopharmaceutical operator that buys or in-licenses early-stage drug candidates, develops them through a network of majority-owned subsidiaries, and then either commercializes them, partners them out, or monetizes them through royalty, milestone, and equity arrangements. The investment case has shifted noticeably over the past twelve months: the company sold its Checkpoint subsidiary to Sun Pharma for $28 million upfront in May 2025, monetized a $205 million Rare Pediatric Disease Priority Review Voucher (a transferable FDA voucher that lets the holder accelerate review of a future drug application) tied to the ZYCUBO approval in March 2026, and exited Baergic to Axsome in November 2025. The result is a meaningfully stronger balance sheet (consolidated cash of $196.6 million at June 30, 2026 versus $79.4 million at year-end 2025) and a portfolio that now looks more like a collection of optionality on partnered programs than a developmental pipeline.
The clearest evidence that the strategic repositioning is working is the six-month 2026 net income figure of $137.8 million, driven almost entirely by the $158.9 million PRV gain. Strip out that one-time payment and the underlying business is still loss-making, although the gap is narrowing: second-quarter 2026 loss from operations improved to $(10.0) million from $(36.5) million a year earlier as the Checkpoint deconsolidation removed the heaviest R&D and SG&A lines. Net product revenue, the only durable top-line driver, grew 19 percent year-over-year in Q2 2026 to $17.8 million, with Emrosi (Journey Medical's rosacea drug) scaling from $2.8 million in Q2 2025 to $8.1 million in Q2 2026.
The market is not paying much for that progress. At a recent $2.84 share price, FBIO trades at a $94.7 million market capitalization, 0.58 times book value, with an enterprise value of negative $6.9 million because the consolidated cash pile exceeds the small market cap. The float is short approximately 21.6 percent, insider ownership sits near 22.7 percent, and the 52-week range of $2.18 to $4.53 frames how much the stock has already moved on each PRV and partnership headline.